Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
8.31
+0.15 (1.84%)
At close: Mar 10, 2026, 4:00 PM EDT
8.41
+0.10 (1.20%)
After-hours: Mar 10, 2026, 7:25 PM EDT
Personalis Revenue
In the year 2025, Personalis had annual revenue of $69.65M, down -17.69%. Personalis had revenue of $17.35M in the quarter ending December 31, 2025, with 3.24% growth.
Revenue (ttm)
$69.65M
Revenue Growth
-17.69%
P/S Ratio
12.48
Revenue / Employee
$267,877
Employees
260
Market Cap
869.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 69.65M | -14.97M | -17.69% |
| Dec 31, 2024 | 84.61M | 11.13M | 15.15% |
| Dec 31, 2023 | 73.48M | 8.43M | 12.97% |
| Dec 31, 2022 | 65.05M | -20.45M | -23.92% |
| Dec 31, 2021 | 85.49M | 6.85M | 8.70% |
| Dec 31, 2020 | 78.65M | 13.44M | 20.61% |
| Dec 31, 2019 | 65.21M | 27.43M | 72.62% |
| Dec 31, 2018 | 37.77M | 28.38M | 302.15% |
| Dec 31, 2017 | 9.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 824.50M |
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| Twist Bioscience | 391.56M |
| CareDx | 379.81M |
| Castle Biosciences | 344.23M |
PSNL News
- 12 days ago - Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights - Business Wire
- 21 days ago - Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference - Business Wire
- 26 days ago - Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 weeks ago - Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance - Business Wire
- 5 weeks ago - Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors - Business Wire
- 5 weeks ago - Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Business Wire
- 2 months ago - Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ - Business Wire